We read the retrospective (July 2015 to July 2016) study with dermatologic data of 2151 patients at Surkhet valley in a Mid-Western Region of Nepal and the findings were considered in accordance with those previously described in diverse other studies.1 Tinea (13.25%), eczema (12.32%), urticaria (9.72%), acne vulgaris (9.21%), pyoderma (8.83%), pityriasis versicolor (7.21%), warts (5.90%), seborrheic dermatitis (5.11%), alopecia areata (4.74%), sexually transmitted infections (3.49%), chicken pox (3.25%), Herpes simplex (2.42%), soft tissue tumors (2.37%), scabies (2.12 %), melasma (2.09%), rosacea (1.16%), Herpes zoster (1.02%), psoriasis (0.93%), candidiasis (0.70%), pityriasis alba (0.56%), pityriasis rosea (0.42%), drug eruption (0.42%), vitiligo (0.37%), bullous disease (0.33%), lichen planus (0.19%), and ichthyosis (0.14%) were reported. The authors highlighted urticarial disorders among the major dermatological changes; while the frequency of viral infections was lower than that reported in several studies.1 As their work only included data from five to six years before the current pandemic, one can rule out the hypothesis that urticaria may be due to infection by SARS-Cov-2 virus; nevertheless, this possibility currently persists unless the test for COVID-19 is negative. Nowadays, the routine of dermatological services should include the specific test to rule out the hypothesis of COVID-19 infection leading to new-onset urticaria manifestations.
